Logo of Myokardia

Bob McDowell Email Address

abcdefghi@myokardia.com

Job Title

Chief Scientific Officer

Company
Myokardia

MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. MyoKardiaaEUR(tm)s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathyaEUR"hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM. MyoKardiaaEUR(tm)s most advanced product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM and is currently being evaluated in three Phase 1 clinical trials. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry, or SHaRe, a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia believes that SHaRe, currently consisting of data from approximately 10,000 individuals, is the worldaEUR(tm)s largest registry of patients with heritable cardiomyopathies. MyoKardiaaEUR(tm)s purpose is to improve the lives of patients and families suffering from cardiovascular disease by creating targeted therapies that can change the course of their condition.

Bio

Robert McDowell has over three decades of experience discovering small molecule drugs in cardiovascular disease, inflammation and oncology, with seven compounds advancing into clinical trials. Dr. McDowell was an integral part of MyoKardia since its inception in 2012, having served as Senior Vice President of Drug Discovery through October 2017, when he was promoted to Chief Scientific Officer. In November 2020, MyoKardia was acquired by Bristol Meyers Squibb. Prior to joining MyoKardia, Dr. McDowell led drug discovery at 3-V Biosciences, advancing the company's lead program into development. He previously served as vice president of research at Sunesis Pharmaceuticals, where he oversaw drug discovery, translational research and manufacturing functions. Dr. McDowell led the structural chemistry group at Axys Pharmaceuticals. Before joining Axys, Dr. McDowell was a senior scientist at Genentech, where he developed successful strategies for peptidomimetic design. Dr. McDowell has authored more than 40 peer-reviewed manuscripts and is an inventor on more than 20 issued U.S. patents. Dr. McDowell holds a B.S. in chemistry and physics from Butler University and a Ph.D. in chemistry from the University of California at Berkeley.

Last University
University of California, Berkeley
Location
Based in Menlo Park.

Other people working at Myokardia:

Paul WoltersVice President, Head of Cardiomyopathy and Heart Failure Clinical Development
Geoff McKinleySenior Director of Marketing
Ben CohnAssociate Director, Strategy and Business Development
Johan OslobSenior Director
Ly KawaguchiExecutive Director
Audrey L White******@myokardia.com
Melissa Masterson**********@myokardia.com
James DriscollScientist II
A. McGuire********@myokardia.com

How does this work?

Anymail finder is trusted by tens of thousands of companies to provide accurate contact information to their Sales and Business Development teams.

If you’re looking to find the email of Bob McDowell at Myokardia then you’ve come to the right place.

Wondering if it's bob@myokardia.com, bob.mcdowell@myokardia.com, mcdowell@myokardia.com, or bmcdowell@myokardia.com? We have the answers for you.

Looking for somebody else’s email?

Find other Emails now